FDA Approves $3.1M Gene Therapy for Rare, Painful Skin DisorderThe FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak EasierThe FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWSFDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to KnowFDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Must-Reads
1
Coupang discloses 33m-user data breach to US regulators
LATEST
2
N. Korea's Kim pays respects to late father at family mausoleum on death anniversary
LATEST
3
Ex-vice land minister arrested over favoritism allegations related to presidential residence relocation
LATEST
4
Seoul stocks open higher amid mixed US job data
LATEST
5
US job growth snaps back; shutdown distorts unemployment rate
FDA Approves $3.1M Gene Therapy for Rare, Painful Skin Disorder The FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier The FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWS FDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to Know FDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Hot Topics